Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis

Objectives The RESOLVE‐1 trial of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc) allowed background immunosuppressive therapy (IST) at the discretion of individual investigators, and no significant differences were observed between treatment arms. This provides a powerful opportunity to c...

Full description

Saved in:
Bibliographic Details
Main Authors: Barbara White, Daniel E. Furst, Tracy M. Frech, Masataka Kuwana, Laura Hummers, Wendy Stevens, Suzanne Kafaja, Eun Bong Lee, Oliver Distler, Dinesh Khanna, Christopher P. Denton, Robert Spiera, for the RESOLVE‐1 investigators
Format: Article
Language:English
Published: Wiley 2025-03-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.70004
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items